Assenagon Asset Management S.A. Sells 24,181 Shares of DaVita Inc. $DVA

Key Points

• Assenagon Asset Management cut its DaVita stake by 54%, selling 24,181 shares in the third quarter and retaining 20,602 shares worth approximately $3.6 million.
• DaVita reported quarterly earnings of $4.02 per share, exceeding estimates of $3.88, while revenue rose 5.2% year over year to $3.55 billion. Management issued fiscal 2026 EPS guidance of $14.10–$15.20.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $233.43, versus the stock’s recent price of $176.65; institutional investors own about 90.12% of shares.

Assenagon Asset Management S.A. lowered its stake in shares of DaVita Inc. (NYSE:DVA - Free Report) by 54.0% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,602 shares of the company's stock after selling 24,181 shares during the period. Assenagon Asset Management S.A.'s holdings in DaVita were worth $3,604,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently modified their holdings of DVA. Value Investment Professionals LLC lifted its position in shares of DaVita by 2.0% in the second quarter. Value Investment Professionals LLC now owns 2,501 shares of the company's stock valued at $556,000 after acquiring an additional 50 shares in the last quarter. Kesler Norman & Wride LLC increased its stake in DaVita by 0.8% in the first quarter. Kesler Norman & Wride LLC now owns 6,816 shares of the company's stock valued at $1,048,000 after purchasing an additional 55 shares during the last quarter. State of Alaska Department of Revenue lifted its position in DaVita by 1.9% during the third quarter. State of Alaska Department of Revenue now owns 3,206 shares of the company's stock worth $560,000 after buying an additional 60 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in DaVita by 4.1% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 1,915 shares of the company's stock worth $426,000 after buying an additional 76 shares during the period. Finally, CoreCap Advisors LLC boosted its stake in DaVita by 161.7% in the 3rd quarter. CoreCap Advisors LLC now owns 157 shares of the company's stock worth $27,000 after buying an additional 97 shares during the last quarter. 90.12% of the stock is currently owned by institutional investors and hedge funds.

DaVita Stock Up 0.7%

Shares of NYSE DVA opened at $176.65 on Thursday. The stock has a market capitalization of $11.27 billion, a P/E ratio of 14.46, a P/E/G ratio of 0.45 and a beta of 0.80. The firm's 50-day moving average price is $180.38 and its two-hundred day moving average price is $191.46. DaVita Inc. has a 52-week low of $101.00 and a 52-week high of $247.49.

DaVita (NYSE:DVA - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, topping the consensus estimate of $3.88 by $0.14. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.50 billion. DaVita had a negative return on equity of 217.63% and a net margin of 6.05%. The firm's revenue for the quarter was up 5.2% on a year-over-year basis. During the same period last year, the company earned $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. As a group, equities research analysts expect that DaVita Inc. will post 14.57 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently commented on DVA shares. Raymond James Financial set a $220.00 price target on shares of DaVita in a research report on Friday, August 7th. Truist Financial cut their price objective on DaVita from $250.00 to $215.00 and set a "hold" rating on the stock in a report on Friday, August 7th. Barclays lifted their price objective on DaVita from $218.00 to $224.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a $265.00 price target on shares of DaVita in a research report on Wednesday, August 5th. Finally, TD Cowen reiterated a "buy" rating on shares of DaVita in a report on Wednesday. Four research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $233.43.

DaVita Profile

DaVita Inc NYSE: DVA is a health care services company focused on kidney care. Through its DaVita Kidney Care business, the company provides outpatient dialysis treatments for people with chronic kidney failure, including in-center hemodialysis, home dialysis and related clinical support services.

DaVita also offers integrated kidney care programs intended to support patients across the stages of chronic kidney disease. Its services may include care coordination, disease management, education, transplant support and other services designed to improve clinical outcomes and help manage the needs of patients with complex kidney conditions.

The company operates a network of dialysis centers and related facilities in the United States and serves patients in select international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.